NCT04330716Completed
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers - GeneBOPP
Source: ClinicalTrials.gov · Last updated 19 Jan 2024
Brief summary (registry, in English)
This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 269 (actual)
- First submitted
- 17 Mar 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Prostate cancer, Pancreatic cancer, Ovarian cancer
- NCT number
- NCT04330716
What you commit to
- Study type: Interventional
- Participants enrolled: 269
- From 1 Dec 2020 to the primary completion date, 31 Dec 2023
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hematologic malignancy (e.g. CLL)
Other
- Pregnant
- Prisoners
- Inability to understand English as a spoken language in a healthcare context
Who the study is looking for
- Potentially eligible participants will be identified via medical record screening and/or in accordance with their clinical visit. A HIPAA waiver of authorization will be obtained by the enrolling Institution as needed to have access to the subject's medical record information for screening of eligibility.
- A member of the study team will approach the potentially eligible participant in clinic and discuss the trial. Potentially eligible participants may choose to discuss participation further with their physician at their appointment
- Age ≥ 18 years
- Breast, ovarian, pancreatic, or metastatic prostate cancer
- No prior cancer genetic testing
- Ability to understand and the willingness to sign an informed consent document
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Dana Farber Cancer Institute At St. Elizabeth'S Medical Center Coordinator of this site? Confirm its status | Brighton | United States | Unknown status |
| Dana-Farber/New Hampshire Oncology-Hematology Coordinator of this site? Confirm its status | Londonderry | United States | Unknown status |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Coordinator of this site? Confirm its status | Milford | United States | Unknown status |
| Lifespan Cancer Institute at Rhode Island Hospital Coordinator of this site? Confirm its status | Providence | United States | Unknown status |
| Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital Coordinator of this site? Confirm its status | Weymouth | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.